During a Case-Based Roundtable® event, Elizabeth A. Brém, MD, discussed treatment approaches for a patient with early relapsed or primary refractory diffuse large B-cell lymphoma in the first article of a 2-part series.
Using a Monoclonal Antibody Plus Chemotherapy in Patients With DLBCL
In the second part of a 2-article series, Matthew A. Lunning, DO, FACP, leads a discussion on how to best manage toxicities from tafasitamab and lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma.
In the first part of a 2-article series, Matthew A. Lunning, DO, FACP, takes into consideration the perspectives of his peers on the use of tafasitamab and lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma.
In the second article of a 2-part series, Hayder Saeed, MD, discusses the long-term use of tafasitamab and lenalidomide in patients with diffuse large B-cell lymphoma and how the combination therapy compares in the real-world setting.
In the first article of a 2-part series, Hayder Saeed, MD, discusses the 5-year follow up data from the L-MIND study, which shows the continuing efficacy of tafasitamab and lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma.
Hayder Saeed, MD, discusses how the mechanism of action of tafasitamab makes the therapy a potent cancer cell killer for patients with diffuse large B-cell lymphoma.
In the second article of a 2-part series, Joseph M. Tuscano, MD, discusses with fellow clinicians what to do for a patient that doesn’t want to undergo CAR T-cell therapy to treat their early-relapse diffuse large B-cell lymphoma.
In the first article of a 2-part series, Joseph M. Tuscano, MD, discusses at a virtual live event with fellow clinicians how to define early-relapsed or primary refractory diffuse large B-cell lymphoma and how this impacts treatments for this patient population.
During a Targeted Oncology™ Case-Based Roundtable™ event, Stephen J. Schuster, MD, discussed the use of tafasitamab plus lenalidomide in patients with diffuse large B-cell lymphoma including managing adverse events and treating patients after disease progression.
During a Targeted Oncology™ Case-Based Roundtable™ event, Stephen A. Schuster, MD, discussed the 5-year outcomes of the L-MIND trial of tafasitamab and lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma.
During a Targeted Oncology™ Case-Based Roundtable™ event, Gilles Salles, MD, discussed the study results and practical considerations for the use of tafasitamab plus lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma.
During a Targeted Oncology™ Case-Based Roundtable™ event, Gilles Salles, MD, discussed when to use CAR T-cell therapy in the second-line setting for patients with relapsed/refractory diffuse large B-cell lymphoma and the outcomes of trials of these agents. This is the first of 2 articles based on this event.
During a live virtual event, Jakub Svoboda, MD, discussed with participants the choice of therapy for a patient with relapsed/refractory diffuse large B-cell lymphoma who would not receive stem cell transplant or chimeric antigen receptor therapy.
During a live virtual event, Brian T. Hill, MD, discussed the results of the L-MIND study of tafasitamab plus lenalidomide for patients with relapsed/refractory diffuse B-cell lymphoma.